Journal: PLOS One

Article Title: Inhibition of neutrophil infiltration and NETs formation ameliorates neuropsychiatric and renal dysfunction in MRL/lpr mice with lupus

doi: 10.1371/journal.pone.0348011

Figure Lengend Snippet: A) Kidney function assessment of various mouse groups at week 20, evaluated by measuring the urine albumin-to-creatinine ratio. B) Upper half: PAS staining of kidney tissue was used to visualize renal tissue architecture and structural injury. Immune cell infiltration was assessed by multiplex immunofluorescence staining for CD11b and CD16; lower half: Multiplex immunofluorescence staining for CD11b, CD16, NE, MPO with localized positive areas enlarged. C) and D) Statistical count of CD11b positive and CD11b/CD16 double-positive cells across different groups. E) and F) Semi-quantitative analysis of fluorescence intensity for NE and MPO in different groups; * indicates comparisons of NE fluorescence intensity, # indicates comparisons of MPO fluorescence intensity. * p < 0.05, ** p < 0.01 compared to the MRL/MpJ group; # p < 0.05, ## p < 0.01 compared to the MRL/lpr+Avacopan group. G) Western blot bands for IL-6, IL-17, TNF-α, and β-actin in different groups. H and I) Semi-quantitative analysis of Western blot results for brain and kidney tissues respectively; * p < 0.05, ** p < 0.01.

Article Snippet: Membranes were incubated with the following primary antibodies overnight at 4°C: IL-6 (1:5000, GB11117-100, Servicebio), IL-17 (1:5000, GB11110-1-100, Servicebio), TNF-α (1:5000, GB115726-100, Servicebio), β-Actin (1:5000, GB15003, Servicebio).

Techniques: Staining, Multiplex Assay, Immunofluorescence, Fluorescence, Western Blot

Journal: Discover Nano

Article Title: Chitosan nanoparticle encapsulated pentoxifylline improves renal protection and reduces oxidative stress in amikacin induced nephrotoxicity

doi: 10.1186/s11671-026-04515-8

Figure Lengend Snippet: Oxidative stress and inflammatory markers in kidney tissue homogenates of different experimental groups showing levels of MDA ( A ), SOD ( B ), GSH ( C ), IL-17 ( D ), TNF-α ( E ), IL-6 ( F ) and CRP ( G ). Data are presented as mean ± SD. Statistical significance was determined by one-way ANOVA followed by Tukey’s post hoc test. Significant differences between groups are indicated by horizontal brackets, with asterisks denoting significance levels ( p < 0.05). ns = not significant

Article Snippet: 1,1-Diphenyl-2-picrylhydrazyl (DPPH) (Sigma-Aldrich, USA) Amikacin (AMK) (Sigma-Aldrich, USA) BioTek Synergy H1 Microplate Reader (BioTek, USA) Bruker D8 Advance X-ray Diffractometer (Bruker, USA) Bruker Tensor II FTIR Spectrometer (Bruker, Germany) Chitosan (medium molecular weight, ≥75% deacetylated) (Sigma-Aldrich, USA) Creatinine Assay Kit (ab65340) (Abcam, USA) Glutathione (GSH) Assay Kit (MBS267424) (MyBioSource, USA) Hitachi SU3500 SEM (Hitachi, Japan) IL-17 ELISA Kit (E-EL-M0047) (Elabscience, USA) JEOL JEM-1400Flash TEM (JEOL, Japan) Malondialdehyde (MDA) Assay Kit (MBS741034) (MyBioSource, USA) Malvern Zetasizer Nano ZS90 (Malvern Panalytical, UK) Pentoxifylline (PTX) (Sigma-Aldrich, USA) Shimadzu UV-1800 Spectrophotometer (Shimadzu, Japan) Sodium Tripolyphosphate (TPP) (Sigma-Aldrich, USA) Superoxide Dismutase (SOD) Assay Kit (MBS2707323) (MyBioSource, USA) Sysmex CA-560 Coagulation Analyzer (Sysmex, Japan) Urea Assay Kit (ab83362) (Abcam, USA) Uric Acid Assay Kit (ab65344) (Abcam, USA)

Techniques:

Journal: Frontiers in Immunology

Article Title: Xinfeng capsule attenuates ankylosing spondylitis by downregulating YTHDC1-mediated m 6 A modification of LINC01579 and suppressing IL-17/NF-κB signaling

doi: 10.3389/fimmu.2026.1762062

Figure Lengend Snippet: Pharmacology of XFC action on AS inflammation network. (A) XFC-AS-inflammation Wayne diagram; (B) XFC-AS-inflammation PPI network; (C) Identification of the top 10 targets of action based on the hubba plugin; (D) XFC component-AS-inflammation-pathway target network diagram; (E) CC bioprocesses; (F) KEGG analysis; (G) IL-17/NF-kB signaling pathway Schematic diagram. Pink squares in D are target genes, red arrows are potential pathways, and green circles are XFC core components.

Article Snippet: In vitro , co-culture experiments were performed using AS-FLSs and AS-PBMCs, with the IL-17 inhibitor Secukinumab (AIN457; Cat# HY-P9927, MCE; 16.2 ng/mL) employed to further elucidate pathway involvement.

Techniques:

Journal: Frontiers in Immunology

Article Title: Xinfeng capsule attenuates ankylosing spondylitis by downregulating YTHDC1-mediated m 6 A modification of LINC01579 and suppressing IL-17/NF-κB signaling

doi: 10.3389/fimmu.2026.1762062

Figure Lengend Snippet: Effects of AS-PBMCs and AS-FLS co-culture model on YTHDC1, LINC01579 and inflammatory cytokines. (A) MeRIP-qPCR for total m6A expression, (B) RT-qPCR for LINC01579 expression; (C) MeRIP-qPCR for LINC0159 m6A expression; (D) RT -qPCR to detect the expression of YTHDC1; (E) WB to detect the expression of YTHDC1; (F) ELISA to detect the expression of IL-6, IL-17 and TNF-a. All experiments were repeated three times. **p<0.01; ***p<0.001.

Article Snippet: In vitro , co-culture experiments were performed using AS-FLSs and AS-PBMCs, with the IL-17 inhibitor Secukinumab (AIN457; Cat# HY-P9927, MCE; 16.2 ng/mL) employed to further elucidate pathway involvement.

Techniques: Co-Culture Assay, Expressing, Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay

Journal: Frontiers in Immunology

Article Title: Xinfeng capsule attenuates ankylosing spondylitis by downregulating YTHDC1-mediated m 6 A modification of LINC01579 and suppressing IL-17/NF-κB signaling

doi: 10.3389/fimmu.2026.1762062

Figure Lengend Snippet: YTHDC1 Regulates LINC01579 Stability and Inflammatory Responses via the MUT1 m6A Site. (A–C) . ELISA to detect the expression of IL-6, IL-17 and TNF-a; (D) RT -qPCR to detect the expression of LINC0159; (E) Radiomycin D assay for LINC0157 stability; (F) WB to detect the expression of iIL-17A, IL-17RA, P-P65. All experiments were repeated three times. **p<0.01; ***p<0.001.

Article Snippet: In vitro , co-culture experiments were performed using AS-FLSs and AS-PBMCs, with the IL-17 inhibitor Secukinumab (AIN457; Cat# HY-P9927, MCE; 16.2 ng/mL) employed to further elucidate pathway involvement.

Techniques: Enzyme-linked Immunosorbent Assay, Expressing, Quantitative RT-PCR

Journal: Frontiers in Immunology

Article Title: Xinfeng capsule attenuates ankylosing spondylitis by downregulating YTHDC1-mediated m 6 A modification of LINC01579 and suppressing IL-17/NF-κB signaling

doi: 10.3389/fimmu.2026.1762062

Figure Lengend Snippet: YTHDC1 regulates the activation of IL-17/NF-kB pathway by modulating the expression of LINC0157 m6A. (A) Nuclear-cytoplasmic fractionation assay to detect the expression of LINC0157; (B) Screening for the optimal small interfering RNA (siRNA) model for LINC0157; (C) RT-qPCR to detect the expression of LINC0157; (D) MeRIP-qPCR detection of LINC0159 m6A expression; (E) ELISA detection of IL-6 and TNF-a expression; (F) Colony formation assay to assess colony formation ability; (G) ELISA detection of IL-17A expression; (H) IF detection of p-P65 expression; (I) Screening for the optimal small interfering RNA model for YTHDC1; (J) RT-qPCR detection of YTHDC1 expression; (K) WB assay for YTHDC1 protein expression. (L) Radiomycin D assay for LINC0157 stability. (M) RT-qPCR assay for LINC0159 expression, (N) MeRIP-qPCR assay for LINC0159 m6A expression. All experiments were repeated three times. *p<0.05; **p<0.01; ***p<0.001.

Article Snippet: In vitro , co-culture experiments were performed using AS-FLSs and AS-PBMCs, with the IL-17 inhibitor Secukinumab (AIN457; Cat# HY-P9927, MCE; 16.2 ng/mL) employed to further elucidate pathway involvement.

Techniques: Activation Assay, Expressing, Fractionation, Small Interfering RNA, Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Colony Assay

Journal: Frontiers in Immunology

Article Title: Xinfeng capsule attenuates ankylosing spondylitis by downregulating YTHDC1-mediated m 6 A modification of LINC01579 and suppressing IL-17/NF-κB signaling

doi: 10.3389/fimmu.2026.1762062

Figure Lengend Snippet: XFC Regulates LINC01579 and Downstream Inflammatory Responses via YTHDC1. (A) RT-qPCR assay to detect YTHDC1 expression, (B) RT-qPCR assay to detect LINC01579 expression, (C–E) . ELISA assay to detect IL-6, IL-17 and TNF-a expression. All experiments were repeated three times. *p < 0.05; **p < 0.01; ***p < 0.001.

Article Snippet: In vitro , co-culture experiments were performed using AS-FLSs and AS-PBMCs, with the IL-17 inhibitor Secukinumab (AIN457; Cat# HY-P9927, MCE; 16.2 ng/mL) employed to further elucidate pathway involvement.

Techniques: Quantitative RT-PCR, Expressing, Enzyme-linked Immunosorbent Assay

Journal: Frontiers in Immunology

Article Title: Xinfeng capsule attenuates ankylosing spondylitis by downregulating YTHDC1-mediated m 6 A modification of LINC01579 and suppressing IL-17/NF-κB signaling

doi: 10.3389/fimmu.2026.1762062

Figure Lengend Snippet: XFC attenuates aberrant methylation and inflammatory response in PGIA mice (A) Study design and experimental schedule; (B) Representative hind paw observations of four groups of PGIA mice; (C) Representative images of Micro-CT scans of spinal joints in three groups, with osteogenesis and stenosis visible in PGIA mice (red arrows); (D) Mouse body weight; (E) Joint scores; (F) ELISA for ALT, AST, CRE (blood and kidney); (G) : ELISA for IL-6, IL-17 and TNF-a expression. (H) MeRIP-qPCR for total m6A expression. (I) RT-qPCR for LINC01579 expression; (J) RT- qPCR to detect the expression of YTHDC1; (K) WB to detect the expression of IL-17 and IL-17A. (L) HE staining of spondyloarthritic joints, PGIA mice were seen with inflammatory cell infiltration and synovial inflammation (black arrowheads), narrowing of joint space, cartilage degradation (green arrows), and bone erosion (yellow arrowheads). (M) Saffron O solid green staining of cartilage degradation was seen in PGIA mice (green arrows). All experiments were repeated three times. *p<0.05; **p<0.017

Article Snippet: In vitro , co-culture experiments were performed using AS-FLSs and AS-PBMCs, with the IL-17 inhibitor Secukinumab (AIN457; Cat# HY-P9927, MCE; 16.2 ng/mL) employed to further elucidate pathway involvement.

Techniques: Methylation, Micro-CT, Enzyme-linked Immunosorbent Assay, Expressing, Quantitative RT-PCR, Staining

Journal: Frontiers in Immunology

Article Title: Xinfeng capsule attenuates ankylosing spondylitis by downregulating YTHDC1-mediated m 6 A modification of LINC01579 and suppressing IL-17/NF-κB signaling

doi: 10.3389/fimmu.2026.1762062

Figure Lengend Snippet: XFC improves AS inflammatory response by upregulating LINC01579 to inhibit IL-17/NF-kB activation (A) Representative hindpaws of five groups of PGIA mice; (B) Arthritis score; (C) ELISA detection of IL-6, IL-17, and TNF-a expression; (D) WB detection of IL-17 and IL-17A expression; (E) Spinal joint HE staining shows inflammatory cell infiltration and synovial inflammation (black arrows), narrowed joint spaces, cartilage degeneration (green arrows), and bone erosion (yellow arrows) in PGIA mice. (F) Fuchsin-O green staining, PGIA mice showed cartilage degeneration (green arrows). (G) RT-qPCR detection of LINC01579 expression in AS-FLS; (H) MeRIP-qPCR assay for LINC0159 m6A expression; (I) ELISA detection of IL-6, IL-17, and TNF-a expression in AS-FLS; (J) IF detection of p-P65 expression. All experiments were repeated three times. *p<0.05; **p<0.01.

Article Snippet: In vitro , co-culture experiments were performed using AS-FLSs and AS-PBMCs, with the IL-17 inhibitor Secukinumab (AIN457; Cat# HY-P9927, MCE; 16.2 ng/mL) employed to further elucidate pathway involvement.

Techniques: Activation Assay, Enzyme-linked Immunosorbent Assay, Expressing, Staining, Quantitative RT-PCR